The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model

Nature Communications

Volumn 7, Issue , 2016, Pages

  Li, Tong ^a   Braunstein, Kerstin E ^a   Zhang, Juhong ^a   Lau, Ashley ^a   Sibener, Leslie ^a   Deeble, Christopher ^a   Wong, Philip C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN; MUTANT PROTEIN;

ANATOMY; BRAIN; DISEASE INCIDENCE; NUMERICAL MODEL; PATHOLOGY; RODENT;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN STEM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; AMINO ACID REPEAT; AMYLOID PLAQUE; ANIMAL; BIOLOGICAL MODEL; BRAIN; CHEMISTRY; DISEASE MODEL; FOREBRAIN; GLIOSIS; HUMAN; METABOLISM; NEURITE; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GLIOSIS; HUMANS; MALE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTANT PROTEINS; NEURITES; PHOSPHORYLATION; PLAQUE, AMYLOID; PROSENCEPHALON; REPETITIVE SEQUENCES, AMINO ACID; TAU PROTEINS;

EID: 84977494752     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12082     Document Type: Article

References (68)

1. Holtzman, D. M., Morris, J. C., & Goate, A. M. Alzheimer?s disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr1 (2011).
2. Hardy, J., & Selkoe, D. J. The amyloid hypothesis of Alzheimer?s disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
3. Selkoe, D., & Kopan, R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565-597 (2003).
4. Lee, V. M., Goedert, M., & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
5. Ballatore, C., Lee, V. M. Y., & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer?s disease and related disorders. Nat. Rev. Neurosci. 8, 663-672 (2007).
6. Bertram, L., & Tanzi, R. E. Thirty years of Alzheimer?s disease genetics: the implications of systematic meta-Analyses. Nat. Rev. Neurosci. 9, 768-778 (2008).
7. Bertram, L., Lill, C. M., & Tanzi, R. E. The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281 (2010).
8. Hardy, J. A., & Higgins, G. A. Alzheimer?s disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
9. Gotz, J., Chen, F., Van Dorpe, J., & Nitsch, R. M. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta fibrils. Science 293, 1491-1495 (2001).
10. Lewis, J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutat tau and APP. Science 293, 1487-1491 (2001).
11. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332 (2004).
12. Oddo, S., et al. Blocking Ab42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein 70-interacting protein: a mechanistic link between alpha beta and tau pathology. J. Neurosci. 28, 12163-12175 (2008).
13. Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. A-inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 29, 1607-1618 (2008).
14. Goate, A., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer?s disease. Nature 349, 704-706 (1991).
15. Sherrington, R., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer?s disease. Nature 375, 754-760 (1995).
16. Strittmatter, W. J., et al. Apolipoprotein E: high-Avidity binding to b-Amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977-1981 (1993).
17. DeMattos, R. B., et al. ApoE and clusterin cooperatively suppress Ab levels and deposition. Evidence that ApoE regulates extracellular Ab metabolism in vivo. Neuron 41, 193-202 (2004).
18. Bu, G. Apolipoprotein E and its receptors in Alzheimer?s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344 (2009).
19. Kim, J., Basak, J. M., & Holtzman, D. M. The role of apolipoprotein E in Alzheimer?s disease. Neuron 63, 287-303 (2009).
20. Guerreiro, R., et al. TREM2 variants in Alzheimer?s disease. N. Engl. J. Med. 368, 117-127 (2013).
21. Jonsson, T., et al. Variant of TREM2 associated with the risk of Alzheimer?s disease. N. Engl. J. Med. 368, 107-116 (2013).
22. Crystal, H. A., et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer?s disease. Neurology 38, 1682-1687 (1988).
23. Katzman, R., et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144 (1988).
24. Price, J. L., & Morris, J. C. Tangles and plaques in nondemented aging and ?preclinical? Alzheimer?s disease. Ann. Neurol. 45, 358-368 (1999).
25. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer?s disease. Neurology 42, 631-639 (1992).
26. Arriagada, P. V., Marzloff, K., & Hyman, B. T. Distribution of Alzheimer-Type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer?s disease. Neurology 42, 1681-1688 (1992).
27. Gomez-Isla, T., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer?s disease. Ann. Neurol. 41, 17-24 (1997).
28. Price, D., Savonenko, A. V., Li, T., Lee, M. K., & Wong, P. in Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics in Protein Misfolding Diseases eds Ramirez-Alvarado, M., Kelly, J. W., & Dobson, C. M.) 233-258 (John Wiley & Sons, Inc., 2010).
29. Gotz, J., & Ittner, L. M. Animal models of Alzheimer?s disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544 (2008).
30. LaFerla, F. M., & Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006320 (2012).
31. Bales, K. R. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer?s disease: an update. Expert. Opin. Drug Discov. 7, 281-297 (2012).
32. Platt, T. L., Reeves, V. L., & Murphy, M. P. Transgenic models of Alzheimer?s disease: better utilization of existing models through viral transgenesis. Biochim. Biophys. Acta 1832, 1437-1448 (2013).
33. Kitazawa, M., Medeiros, R., & LaFerla, F. M. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr. Pharm. Des. 18, 1131-1147 (2012).
34. Oddo, S., et al. Triple-Transgenic model of Alzheimer?s disease with plaques and tangles: intracellular Ab and synaptic dysfunction. Neuron 39, 409-421 (2003).
35. Lewis, J., et al. Neurofibrillary tangles, amyotrophy and progressive disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405 (2000).
36. Yoshiyama, Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse mode (vol 53, pg 337, 2007). Neuron 54, 343-344 (2007).
37. SantaCruz, K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
38. Hsiao, K., et al. Correlative memory deficts, Ab elevation and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
39. Oakley, H., et al. Intraneuronal b-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer?s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006).
40. Sturchler-Pierrat, C., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 13287-13292 (1997).
41. Duff, K., et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7, 87-98 (2000).
42. Winton, M. J., et al. Intraneuronal APP, not free Ab peptides in 3xTg-AD mice: implications for tau versus Ab-mediated Alzheimer neurodegeneration. J. Neurosci. 31, 7691-7699 (2011).
43. Sanders, D. W., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271-1288 (2014).
44. Hutton, M., et al. Association of missense and 5?-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
45. Wang, Y. P., Biernat, J., Pickhardt, M., Mandelkow, E., & Mandelkow, E. M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl Acad. Sci. USA 104, 10252-10257 (2007).
46. Irwin, D. J., et al. Acetylated tau, a novel pathological signature in Alzheimer?s disease and other tauopathies. Brain 135, 807-818 (2012).
47. Cohen, T. J., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011).
48. Jankowsky, J. L., et al. Persistent amyloidosis following suppression of Ab production in a transgenic model of Alzheimer disease. PLoS.Med. 2, e355 (2005).
49. Jankowsky, J. L., Xu, G., Fromholt, D., Gonzales, V., & Borchelt, D. R. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol. Exp. Neurol 62, 1220-1227 (2003).
50. Mocanu, M. M., et al. The potential for beta-structure in the repeat domain of Tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 28, 737-748 (2008).
51. Harold, D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer?s disease. Nat. Genet. 41, 1088-1093 (2009).
52. Lambert, J. C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer?s disease. Nat. Genet. 41, 1094-1099 (2009).
53. Hollingworth, P., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer?s disease. Nat. Genet. 429-435 (2011).
54. Naj, A. C., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset alzheimer?s disease. Nat. Genet. 43, 436-441 (2011).
55. Jack Jr C. R., & Holtzman, D. M. Biomarker modeling of Alzheimer?s disease. Neuron 80, 1347-1358 (2013).
56. Jack Jr C. R., et al. Tracking pathophysiological processes in Alzheimer?s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 207-216 (2013).
57. Choi, S. H., et al. A three-dimensional human neural cell culture model of Alzheimer?s disease. Nature (2014).
58. Golde, T. E., Schneider, L. S., & Koo, E. H. Anti-Ab therapeutics in Alzheimer?s disease: the need for a paradigm shift. Neuron 69, 203-213 (2011).
59. Sperling, R. A., Jack Jr C. R., & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 30, 111cm33 (2011).
60. Salloway, S., Sperling, R., & Brashear, H. R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer?s disease. N. Engl. J. Med. 370, 1460 (2014).
61. Doody, R. S., Farlow, M., & Aisen, P. S. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer?s disease. N. Engl. J. Med. 370, 1460 (2014).
62. Mayford, M., et al. Control of memory formation through regulated expression of a CaMKII transgene. Science 274, 1678-1683 (1996).
63. Li, T., Ma, G., Cai, H., Price, D. L., & Wong, P. C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate notch signaling and for processing and trafficking of b-Amyloid precursor protein in mammals. J. Neurosci. 23, 3272-3277 (2003).
64. Li, T., et al. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 27, 10849-10859 (2007).
65. Yamamoto, T., & Hirano, A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer?s neurofibrillary tangles. Neuropathol. Appl. Neurobiol. 12, 3-9 (1986).
66. Borchelt, D. R., et al. Familial Alzheimer?s disease-linked presenilin 1 variants elevate Ab1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996).
67. Braak, H., & Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
68. Mirra, S. S., Hart, M. H., & Terry, R. D. Making the diagnosis of Alzheimer?s disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 117, 132-144 (1993).